South Korea · Delayed Price · Currency is KRW Whan In Pharm Statistics
Total Valuation
Whan In Pharm has a market cap or net worth of KRW 162.14 billion. The enterprise value is 103.21 billion.
| Market Cap | 162.14B |
| Enterprise Value | 103.21B |
Important Dates
The next estimated earnings date is Friday, February 13, 2026.
| Earnings Date | Feb 13, 2026 |
| Ex-Dividend Date | Dec 29, 2025 |
Share Statistics
Whan In Pharm has 15.27 million shares outstanding. The number of shares has increased by 1.53% in one year.
| Current Share Class | 15.27M |
| Shares Outstanding | 15.27M |
| Shares Change (YoY) | +1.53% |
| Shares Change (QoQ) | +5.98% |
| Owned by Insiders (%) | 28.36% |
| Owned by Institutions (%) | 15.10% |
| Float | 10.94M |
Valuation Ratios
The trailing PE ratio is 10.85 and the forward PE ratio is 11.50.
| PE Ratio | 10.85 |
| Forward PE | 11.50 |
| PS Ratio | 0.63 |
| PB Ratio | 0.41 |
| P/TBV Ratio | 0.42 |
| P/FCF Ratio | 28.56 |
| P/OCF Ratio | 15.74 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 4.46, with an EV/FCF ratio of 18.18.
| EV / Earnings | 6.80 |
| EV / Sales | 0.40 |
| EV / EBITDA | 4.46 |
| EV / EBIT | 7.75 |
| EV / FCF | 18.18 |
Financial Position
The company has a current ratio of 5.55, with a Debt / Equity ratio of 0.00.
| Current Ratio | 5.55 |
| Quick Ratio | 3.24 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | 0.03 |
| Debt / FCF | 0.13 |
| Interest Coverage | 456.42 |
Financial Efficiency
Return on equity (ROE) is 3.95% and return on invested capital (ROIC) is 2.02%.
| Return on Equity (ROE) | 3.95% |
| Return on Assets (ROA) | 1.80% |
| Return on Invested Capital (ROIC) | 2.02% |
| Return on Capital Employed (ROCE) | 3.10% |
| Revenue Per Employee | 426.49M |
| Profits Per Employee | 25.24M |
| Employee Count | 601 |
| Asset Turnover | 0.59 |
| Inventory Turnover | 2.20 |
Taxes
In the past 12 months, Whan In Pharm has paid 637.11 million in taxes.
| Income Tax | 637.11M |
| Effective Tax Rate | 4.03% |
Stock Price Statistics
The stock price has decreased by -11.47% in the last 52 weeks. The beta is 0.20, so Whan In Pharm's price volatility has been lower than the market average.
| Beta (5Y) | 0.20 |
| 52-Week Price Change | -11.47% |
| 50-Day Moving Average | 11,422.60 |
| 200-Day Moving Average | 11,483.20 |
| Relative Strength Index (RSI) | 25.67 |
| Average Volume (20 Days) | 32,817 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Whan In Pharm had revenue of KRW 256.32 billion and earned 15.17 billion in profits. Earnings per share was 978.53.
| Revenue | 256.32B |
| Gross Profit | 84.07B |
| Operating Income | 12.45B |
| Pretax Income | 15.80B |
| Net Income | 15.17B |
| EBITDA | 22.27B |
| EBIT | 12.45B |
| Earnings Per Share (EPS) | 978.53 |
Balance Sheet
The company has 59.69 billion in cash and 760.47 million in debt, with a net cash position of 58.93 billion or 3,859.83 per share.
| Cash & Cash Equivalents | 59.69B |
| Total Debt | 760.47M |
| Net Cash | 58.93B |
| Net Cash Per Share | 3,859.83 |
| Equity (Book Value) | 393.81B |
| Book Value Per Share | 25,794.90 |
| Working Capital | 178.67B |
Cash Flow
In the last 12 months, operating cash flow was 10.30 billion and capital expenditures -4.63 billion, giving a free cash flow of 5.68 billion.
| Operating Cash Flow | 10.30B |
| Capital Expenditures | -4.63B |
| Free Cash Flow | 5.68B |
| FCF Per Share | 371.87 |
Margins
Gross margin is 32.80%, with operating and profit margins of 4.86% and 5.92%.
| Gross Margin | 32.80% |
| Operating Margin | 4.86% |
| Pretax Margin | 6.17% |
| Profit Margin | 5.92% |
| EBITDA Margin | 8.69% |
| EBIT Margin | 4.86% |
| FCF Margin | 2.21% |
Dividends & Yields
This stock pays an annual dividend of 300.00, which amounts to a dividend yield of 2.82%.
| Dividend Per Share | 300.00 |
| Dividend Yield | 2.82% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 30.20% |
| Buyback Yield | -1.53% |
| Shareholder Yield | 1.32% |
| Earnings Yield | 9.35% |
| FCF Yield | 3.50% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on April 14, 2010. It was a forward split with a ratio of 2.
| Last Split Date | Apr 14, 2010 |
| Split Type | Forward |
| Split Ratio | 2 |
Scores
Whan In Pharm has an Altman Z-Score of 4.64 and a Piotroski F-Score of 4.
| Altman Z-Score | 4.64 |
| Piotroski F-Score | 4 |